FOR IMMEDIATE RELEASE
Contacts: Media:
Heather Kowalski
240-453-3343
Investors:
Charles Poole
203-761-5400
Celera Genomics Completes Acquisition of Paracel, Inc.
ROCKVILLE, MD--June 9, 2000--Celera Genomics (NYSE: CRA), a PE Corporation
business, today announced that it had completed the acquisition of Paracel,
Inc., a privately-held company based in Pasadena, CA. Paracel is a leading
producer of advanced genomic and text analysis supercomputing technology. As a
result of the merger, all of the equity of Paracel was exchanged for
approximately 2.26 million shares of Celera Genomics common stock. The
transaction was structured as a tax-free reorganization and accounted for under
the purchase method.
PE Corporation comprises two operating groups. The Celera Genomics Group (NYSE:
CRA), headquartered in Rockville, MD, intends to become the definitive source of
genomic and related medical information. The PE Biosystems Group (NYSE: PEB),
with sales of $1.2 billion during fiscal 1999, develops and markets
instrument-based systems, reagents, software and contract services to the life
science industry and research community. PE Biosystems is headquartered in
Foster City, CA, and comprises four divisions: Applied Biosystems, PE
Informatics, PerSeptive Biosystems, and Tropix. Information about the Company,
including reports and other information filed by the Company with the Securities
and Exchange Commission, is available on the worldwide web at
www.pecorporation.com or by phoning 800.762.6923.
Copyright (c) 2000 . PE Corporation. All Rights Reserved.
Celera, Celera Genomics, and PE Biosystems are trademarks of PE Corporation.
# # #
